Inhalable drug developer MAP Pharmaceuticals files for IPO

MAP Pharmaceuticals, which develops inhalable drugs to treat migraine and pediatric asthma, filed for IPO Monday. Merrill Lynch, Morgan Stanley, and Deutsche Bank are the underwriters on the deal.